PFG Private Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

PFG Private Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51.9K	Buy	+37,335	New	+$51.3K	0.02%	74

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFG Private Wealth Management's AKBA Position: Q1 2026 in Review

PFG Private Wealth Management opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 37,335 shares worth $51.9K. The stake represents 0.02% of the portfolio and ranks #74 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

PFG Private Wealth Management held 37,335 shares of Akebia Therapeutics worth $51.9K as of Q1 2026.
Akebia Therapeutics was a new PFG Private Wealth Management position in Q1 2026.
Akebia Therapeutics made up 0.02% of PFG Private Wealth Management's portfolio in Q1 2026, its #74 holding.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on PFG Private Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.